Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? (Q36839693)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 2007

Language	Label	Description	Also known as
English	Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin?	scientific article published on June 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

methicillin-resistant Staphylococcus aureus

0 references

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

Henry F Chambers

1

object named as

Henry F Chambers

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

author name string

Sharath S Hegde

2

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Expert Review of Anti-infective Therapy

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

333-335

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Community-associated MRSA--resistance and virulence converge

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

The management of infections due to drug-resistant gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Limitations of presently available glycopeptides in the treatment of Gram-positive infection

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Vancomycin-resistant enterococcal infections

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Quinupristin-dalfopristin and linezolid: evidence and opinion

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

A review of linezolid: the first oxazolidinone antibiotic

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Linezolid resistance in a clinical isolate of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Clinical characteristics of linezolid-resistant Staphylococcus aureus infections.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Tigecycline: a new glycylcycline for treatment of serious infections

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.333

21 January 2018

Identifiers

10.1586/14787210.5.3.333

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36839693&oldid=1783870696"